Characteristics and Conflicts of Public Speakers at Meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration

Abola, M. V. & Prasad, V. JAMA Internal Medicine. Published online February 01, 2016

This study reviewed transcripts of meetings of the Oncologic Drugs Advisory Committee to the US Food and Drug Administration to characterize potential financial and other conflicts of interest of public speakers.

The Oncologic Drugs Advisory Committee advises the US Food and Drug Administration (FDA) about medications for the treatment of cancer. The committee’s meeting agenda typically includes presentations by both a company seeking marketing approval for an oncologic drug that it sponsors and by the FDA, as well as a public hearing for comments by other speakers. Speakers may be patients with cancer or may represent patient advocacy organizations, and speakers are asked to disclose financial associations with the sponsoring company or other relevant financial associations.

Read the abstract here

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s